In today’s Blitz Daily with Lance Ippolito, we take a look at pharmaceutical company Merck.
Merck uses leading-edge science to develop vaccines and medicines for the prevention and treatment of numerous diseases and ailments.
The company announced on Thursday that V116, its pneumococcal conjugate vaccine, had received a breakthrough therapy designation from the U.S. Food and Drug Administration.
While that sounds like a mouthful, just know that pneumococcal disease is an infection that causes illnesses like pneumonia and meningitis.
And the breakthrough therapy designation means Merck will get more guidance from the FDA on development as well as access to a scientific liaison to help speed up the review process.
This means good things should be ahead for the company, and the bulls are betting on it…
But that’s not the only flow we saw ahead of a long holiday weekend…
Disclaimer : The material in this document is for informational purposes based on our proprietary research. It is not an offering, specific recommendation, or a solicitation of an offer to buy or sell any securities mentioned or discussed herein.
Any performance results discussed herein represent past performance, are not a guarantee of future performance, and are not indicative of any specific investment.
Due to the timing of information presented, any investment performance reflected within this document may be adjusted after the publication and distribution of this material. There can be no assurance that the future performance of any specific investment, investment strategy, or product made reference to directly or indirectly in this communication will be profitable, be equal to any corresponding indicated historical performance levels or be suitable for your portfolio. Any investment results set forth in this document are not net of expenses and execution costs, nor do they account for other relevant trading or investment fees. Please visit wealthpress.com/terms for our full Terms and Conditions.
0 Response to "Merck’s Latest Drug Approval Sparks Big Earnings Bet"
Post a Comment